Published in Int J Mol Med on July 01, 2004
Transient knockdown and overexpression reveal a developmental role for the zebrafish enosf1b gene. Cell Biosci (2011) 1.14
Androgen and its receptor promote Bax-mediated apoptosis. Mol Cell Biol (2006) 1.10
Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity. Prostate (2007) 1.03
Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult. Cancer Res (2006) 0.99
β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK. Int J Oncol (2013) 0.94
p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle (2012) 0.83
XAF1 expression and regulatory effects of somatostatin on XAF1 in prostate cancer cells. J Exp Clin Cancer Res (2010) 0.81
Molecular targets for radiation oncology in prostate cancer. Front Oncol (2011) 0.78
When chronic conditions become acute: prevention and control of chronic diseases and adverse health outcomes during natural disasters. Prev Chronic Dis (2005) 2.03
Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J (2005) 1.56
Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med (2004) 1.38
Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep (2004) 1.27
In vitro combination characterization of the new anticancer plant drug beta-elemene with taxanes against human lung carcinoma. Int J Oncol (2007) 1.26
Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res (2004) 1.24
Enhancing response rates in physician surveys: the limited utility of electronic options. Health Serv Res (2011) 1.22
Development of a federally funded demonstration colorectal cancer screening program. Prev Chronic Dis (2008) 1.19
CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin Exp Metastasis (2012) 1.18
beta-Elemene, a novel plant-derived antineoplastic agent, increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis. Oncol Rep (2009) 1.11
Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications. Mol Cancer Ther (2011) 1.10
CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer. Mol Cancer (2004) 1.08
Neuro-optic cell apoptosis and microangiopathy in KKAY mouse retina. Int J Mol Med (2004) 1.02
Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance. Carcinogenesis (2012) 1.00
Antineoplastic effect of beta-elemene on prostate cancer cells and other types of solid tumour cells. J Pharm Pharmacol (2010) 1.00
Molecular mechanism of antitumor activity of taxanes in lung cancer (Review). Int J Oncol (2005) 0.97
Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines. Cancer Gene Ther (2002) 0.97
Suramin's development: what did we learn? Invest New Drugs (2002) 0.97
ATM-dependent CHK2 activation induced by anticancer agent, irofulven. J Biol Chem (2004) 0.96
Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res (2003) 0.96
Detection of cyclin b1 expression in g(1)-phase cancer cell lines and cancer tissues by postsorting Western blot analysis. Cancer Res (2004) 0.95
Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther (2003) 0.95
Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int J Mol Med (2006) 0.95
Evaluation of cisplatin in combination with β-elemene as a regimen for prostate cancer chemotherapy. Basic Clin Pharmacol Toxicol (2010) 0.94
Hedgehog signaling pathway regulates the growth of ovarian cancer spheroid forming cells. Int J Oncol (2011) 0.94
Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing Escherichia coli bacteremia. Int J Mol Med (2006) 0.94
β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK. Int J Oncol (2013) 0.94
CD4+ T cells and the Th1/Th2 imbalance are implicated in the pathogenesis of Graves' ophthalmopathy. Int J Mol Med (2006) 0.92
Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer. Oncol Rep (2011) 0.91
SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem Biophys Res Commun (2004) 0.91
BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven. Mol Pharmacol (2007) 0.91
Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1. Mol Cancer Ther (2008) 0.90
Dual regulation of soluble tumor necrosis factor-alpha induced activation of human monocytic cells via modulating transmembrane TNF-alpha-mediated 'reverse signaling'. Int J Mol Med (2006) 0.89
MZF1 possesses a repressively regulatory function in ERCC1 expression. Biochem Pharmacol (2006) 0.88
β-elemene effectively suppresses the growth and survival of both platinum-sensitive and -resistant ovarian tumor cells. Anticancer Res (2012) 0.88
Protein phosphatase 2A interacts with Chk2 and regulates phosphorylation at Thr-68 after cisplatin treatment of human ovarian cancer cells. Int J Mol Med (2006) 0.88
ERCC1 measurements in clinical oncology. N Engl J Med (2006) 0.88
The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity. Mutat Res (2011) 0.87
Transcription factor E2F-1 is upregulated in human gastric cancer tissues and its overexpression suppresses gastric tumor cell proliferation. Cell Oncol (2007) 0.87
Inducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cells. Biochem Biophys Res Commun (2005) 0.87
Effects of Kupffer cell inhibition on liver function and hepatocellular activity in mice. Int J Mol Med (2003) 0.87
Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer. Cancer Biol Ther (2010) 0.86
Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. J Clin Oncol (2003) 0.86
Enhancement of cisplatin-induced apoptosis by β-elemene in resistant human ovarian cancer cells. Med Oncol (2013) 0.86
β-Elemene promotes cisplatin-induced cell death in human bladder cancer and other carcinomas. Anticancer Res (2013) 0.86
Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer. World J Urol (2004) 0.85
Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven. Mol Cancer Ther (2006) 0.85
9-beta-D-arabinofuranosyl-2-fluoroadenine inhibits expression of vascular endothelial growth factor through hypoxia-inducible factor-1 in human ovarian cancer cells. Mol Pharmacol (2004) 0.85
Evaluation of combination gene therapy with PTEN and antisense hTERT for malignant glioma in vitro and xenografts. Cell Mol Life Sci (2007) 0.85
Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells. Int J Oncol (2004) 0.84
The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer. Urol Int (2002) 0.84
Epothilones: a novel class of non-taxane microtubule-stabilizing agents. Curr Pharm Des (2002) 0.84
Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of β-elemene and its synthetic analogs. Med Oncol (2013) 0.83
The human WW45 protein enhances MST1-mediated apoptosis in vivo. Int J Mol Med (2009) 0.83
A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecol Oncol (2005) 0.83
Subcellular localization of caspase-3 activation correlates with changes in apoptotic morphology in MOLT-4 leukemia cells exposed to X-ray irradiation. Int J Oncol (2005) 0.82
Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma. Int J Mol Med (2004) 0.81
Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies. J Clin Pharmacol (2003) 0.81
Overexpression of the N-terminal end of the p55gamma regulatory subunit of phosphatidylinositol 3-kinase blocks cell cycle progression in gastric carcinoma cells. Int J Oncol (2005) 0.81
Double prophylaxis for deep venous thrombosis in patients with gynecologic oncology who are undergoing laparotomy: does preoperative anticoagulation matter? Int J Gynecol Cancer (2011) 0.81
Irofulven induces replication-dependent CHK2 activation related to p53 status. Biochem Pharmacol (2006) 0.81
Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival? Int J Gynecol Cancer (2012) 0.80
A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer. Acta Oncol (2003) 0.80
Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy. Cancer Chemother Pharmacol (2013) 0.80
Vascular endothelium summary statement VI: Research directions for the 21st century. Vascul Pharmacol (2006) 0.80
Characterization of the mechanisms of electrochemotherapy in an in vitro model for human cervical cancer. Int J Oncol (2005) 0.80
Differential expression of cyclins A, B1, D3 and E in G1 phase of the cell cycle between the synchronized and asynchronously growing MOLT-4 cells. Int J Mol Med (2005) 0.79
Timing of apoptosis onset depends on cell cycle progression in peripheral blood lymphocytes and lymphocytic leukemia cells. Oncol Rep (2007) 0.79
β-Elemene and taxanes synergistically induce cytotoxicity and inhibit proliferation in ovarian cancer and other tumor cells. Anticancer Res (2013) 0.79
A Polymorphic Variant of AFAP-110 Enhances cSrc Activity. Transl Oncol (2010) 0.78
Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N? BMJ Open (2013) 0.78
Leptomeningeal carcinomatosis in metastatic prostate cancer. South Med J (2002) 0.78
Effects of thalidomide on the expression of angiogenesis growth factors in human A549 lung adenocarcinoma cells. Int J Mol Med (2003) 0.78
Self-test device for cytology and HPV testing in rural Appalachian women: an evaluation. J Reprod Med (2008) 0.77
Down-regulation of cyclin E expression by caffeine promotes cancer cell entry into the S-phase of the cell cycle. Anticancer Res (2004) 0.77
Colorectal cancer screening practices in Alabama: a survey of primary care physicians. J Cancer Educ (2012) 0.76
Duration of cisplatin excretion in breast milk. J Hum Lact (2013) 0.76
Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. Cancer Chemother Pharmacol (2004) 0.76
Antisense telomerase RNA inhibits the growth of human glioma cells in vitro and in vivo. Int J Oncol (2006) 0.76
Cytokinetic analysis of cell cycle and sub-phases in MOLT-4 cells by cyclin E + A/DNA multiparameter flow cytometry. Oncol Rep (2002) 0.75
Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis. Oncol Rep (2005) 0.75